Introduction 13
Staphylococcus aureus is a ubiquitous and highly adaptable human pathogen 14 responsible for a significant global burden of morbidity and mortality. The bacterium 15 lives as a commensal in the nares of 20-25% of the population at any one time (1, 2). 16
While nasal colonisation is a well-established risk factor for most types of S. aureus 17 infections, several recent studies have suggested that colonisation of the intestine, 18 which occurs in c. 20% of individuals and which by and large has been overlooked, 19
could have important clinical implications (3). Patients with S. aureus intestinal 20
colonisation can serve as an important source of transmission, as they often 21 contaminate the adjacent environment (4). Similarly, such patients display an 22 increased frequency of skin colonisation (5). A study in intensive care and liver 23 transplant units showed that patients with both rectal and nares colonisation by MRSA 24 had a significantly higher risk of disease (40%) than did patients with nasal 25 colonisation alone (18%) (6). Furthermore, a study of hospitalised patients in the 26
United States reported co-colonisation by S. aureus and vancomycin-resistant 27 enterococci in >50% of the individuals studied (7). Thus it is likely that intestinal 28 colonisation by S. aureus provides the pathogen with a potential opportunity to 29 acquire new antibiotic resistance genes. 30
31
While the clinical implications of intestinal colonisation by S. aureus are still 32 relatively ill-defined, it is assumed that carriage is a risk for intestinal infection; S. 33 aureus can induce pseudomembranous colitis that is histologically distinct from that 34
caused by Clostridium difficile (8). Multiple studies have demonstrated frequent 35
intestinal colonisation in infants, particularly in those that were breast-fed and that a 36 positive correlation exists with development of allergies (9-13). While a role for S. 37
6
Generation of an in-frame mnhF mutant.
88
For the ∆mnhF, DNA fragments corresponding to c. 0.7 kb upstream and downstream of 89 mnhF were amplified using Pwo polymerase (Roche) with primers 90 ∆mnhFLFor/∆mnhFLRev and ∆mnhFRFor/∆mnhFRRev (Table 3) . Following 91 purification, PCR products were digested with BamHI/EcoRI and cloned into pMAD.
92
The resulting plasmid was used to transform electrocompetent S. aureus RN4220 (24).
93
Plasmids were transduced into SH1000 using φ11 phage. The temperature sensitive 94 nature of plasmid replication was exploited to integrate the plasmid into the bacterial 95 chromosome, by plating cells on media containing erythromycin and lincomycin at 42ºC.
96
After further rounds of plating, erythromycin and lincomycin sensitive colonies were 97 isolated and the loss of mnhF confirmed by PCR.
99
Cloning and expression of mnhF.
100
The mnhF gene was amplified by PCR with S. aureus SH1000 DNA. For cloning into S.
101
aureus, mnhFFor2 and mnhFRev (Table 3) were used. PCR products were digested with
102
EcoRI and BamHI and ligated into similarly digested pRMC2. This created pMnhF2,
103
where mnhF is fused to P xyl/tetO , which is under the control of TetR and induced with 104 anydrotetracycline. For cloning into E. coli, oligonucleotides mnhFFor1 and mnhFRev 105 (Table 3) mRNAs from mutant and wild type strains were quantified using quantitative real-128 time PCR (qRT-PCR). Cells were grown in triplicate as described above, then treated 129 with RNA protect (Qiagen) and RNA was isolated using the Qiagen RNeasy Mini kit. 130 DNA was removed using Turbo DNase-free (Life Technologies). Purified RNA was 131 quantified using a nonodrop ND-1000 spectrophotometer (Thermo Scientific). 0.5 µg 132 of RNA was reverse transcribed using the Tetro cDNA synthesis kit (Bioline). qRT-133 PCR was performed using the Aligent qPCR System and iQ SYBR Green Supermix 134 (Biorad). The relative amounts of RNAIII mRNA in parental wild type and mutant 135 cells was determined by relative quantification using gyrB, based on consistent levels 136 observed in previous studies (26, 27, 28, 29) . The oligonucleotides used for qRT-137 PCR are listed in Table 3 . 138 8 139
Three-stage continuous culture colonic model system (human gut model). 140
The three-stage continuous culture model of the human colon has been described 141 previously (16, 30). The experiment was carried out in triplicate using faecal samples 142 from three different volunteers. After obtaining verbal informed consent, a standard 143 questionnaire to collect information regarding the health status, drugs use, clinical 144 anamnesis, and lifestyle was administrated before the donor was ask to provide a 145 faecal sample. No volunteers had received antibiotics, probiotics, steroids or other 146 drugs with a proven impact on gut microbiota for at least 3 months before sampling. 147
None of them had any history of gastrointestinal disorder. All healthy faecal donors 148 had the experimental procedure explained to them and were given the opportunity to 149 ask questions. The University of Reading research Ethics Committee exempted this 150 study from review because no donors were involved in any intervention and waived 151 the need for written consent due to the fact the samples received were not collected by 152 means of intervention. All faecal samples were collected on site, kept in an anaerobic 153 cabinet (10 % H 2 , 10 % CO 2 and 80 % N 2 ) and used within a maximum of 15 minutes 154 after collection. Samples were diluted 1/10 w/v in anaerobic PBS (0.1 mol/l phosphate 155 buffer solution, pH 7.4) and homogenized (Stomacher 400, Seward, West Sussex, 156 UK) for 2 minutes at 460 paddle-beats. 157
158
Samples were plated onto BHI agar containing 0.01% (w/v) potassium tellurite as a 159 selective agent at different dilutions in PBS (from 10 2 to 10 9 CFU/ml) in triplicate for 160 each time point to measure bacterial counts. 161
162

Statistical analysis 163
All experiments were repeated three times and data were presented as ± standard error 164 of mean. Analysis was performed using GraphPad Prism 5 software. Experimental 165 data were analysed by One-Way Anova and Two-Way Anova method, using 166
Bonferroni post-test analysis. 167
168
Results
169
Identification of a bile salt resistance locus. 170
Genes conferring resistance to bile were identified by replica plating S. aureus 171 SH1000 Tn917 insertion libraries on BHI agar and onto BHI agar containing 18% 172 (w/v) bile salts (Oxoid), which represented 0.8 Í MIC. Six colonies were unable to 173 grow in the presence of bile salts, but exhibited no growth defect on BHI agar in the 174 absence of bile. Sequencing of the genomic DNA flanking the transposon insertion 175 site of bile sensitive strains was carried out in order to identify the DNA insertion 176 sites of Tn917, revealing that all six strains were siblings containing the transposon 177 inserted in the same gene, namely the previously described mnhA, the first gene in the 178 polycistronic mnhABCDEFG operon which encodes a Na + /H + antiporter (31). 179
Bacillus subtilis contains the orthologous mrpABCDEFG operon that has an identical 180 function, however mrpF and by extension mnhF, are homologous to mammalian bile 181 transporters and mrpF mediates cholic acid efflux (32, 33). 182
183
MnhF mediates resistance to bile salts. 184
We hypothesized that MnhF was responsible for the observed bile salt resistance 185 phenotype. To test this, an in-frame ∆mnhF strain was created in S. aureus SH1000. 186
The mutant strain had no growth defect when grown on BHI solid or liquid media in 187 the absence of bile salts (results not shown). Compared to the parental wild type, the 188 ∆mnhF strain had a reduced MIC for unconjugated bile salts and, in particular, cholic 189 acid (Table 4) . Complementation of mutation with mnhF under the control of an 190 inducible promoter restored the bile resistance phenotype to that observed in the 191 parent strain in the presence of anhydrotetracycline as an inducer (Table 4) , whereas 192
there was no such resistance in the absence of the inducer (results not shown). In 193 killing assays, the ∆mnhF strain was significantly more sensitive than the parent. In 194 the presence of 1 µg/mL anhydrotetracycline, the complemented strain exhibited a 195 similar rate of cell death as the parental wild type (Fig 1) . The increased sensitivity of 196 the mutant strain was only observed with unconjugated bile salts. However it should 197 be noted that we were unable to determine the MIC of conjugated bile salts for S. Given the ability of MnhF to confer bile salt resistance and its similarity to other 212 known and putative bile efflux systems, its ability to mediate removal of cholic acid 213 from bacteria was tested. Both Phe-Arg-β-naphthylamide (PAβN), a synthetic 214 dipeptide that inhibits bacterial efflux pumps, including bile salt efflux pumps of 215
Gram negative bacteria, and reserpine, a plant alkaloid which can inhibit multidrug 216 efflux pumps in Gram positive bacteria, were tested for their ability to reduce bile salt 217
MICs in S. aureus. Both inhibitors caused reductions in the S. aureus MIC for cholic 218
acid and PAβN reduced the MIC for all three unconjugaged bile salts (Table 6A) , 219 however the reduction was much smaller in the ∆mnhF strain than the parental wild-220 type, possibly indicating the presence of other bile salt efflux systems in the pathogen. 221
Similarly, in E. coli (pMnhF1), PAβN reduced bile salt MICs to levels lower than that 222
for untreated E. coli (pBAD His A) (Table 6B ). Thus in both S. aureus and E. coli, 223 inhibitors of efflux pumps abrogated bile salt resistance in an MnhF dependent 224
manner. 225 226
MnhF transports cholic acid. 227
Given the ability of efflux pump inhibitors to reduce the MICs of certain bile salts in 228 S. aureus, the capacity of the MnhF to transport cholic acid was determined in 229 vitro using a 14 C-radiolabelled cholic acid substrate, similar to previous efflux assays 230 (25, 34, 35). S. aureus SH1000 and ∆mnhF strains were incubated with 14 C-cholic 231 acid (uptake period) and then diluted in buffer containing excess of non-radiolabelled 232 cholic acid (efflux period). Initial 14 C-cholic acid uptake was the same for both 233 strains (10962 ± 550 cpm for S. aureus SH1000 and 10278 ± 278 cpm for S. aureus 234 ∆mnhF), but throughout the efflux period S. aureus ∆mnhF retained significantly 235 more of the radiolabel than the parental wild-type (Fig 3A) . To further corroborate 236 these findings, efflux assays were also carried out on E. coli expressing MnhF. E. coli 237 TG1, E. coli TG1 (pBAD) and E. coli TG1 (pMnhF1) were grown overnight in LB 238 supplemented with 1% arabinose at 37°C, then incubated with 14 C-cholic acid. All 239 the E. coli TG1 strains incorporated similar levels of 14 C-cholic acid during uptake 240 period (20774 ± 363 for TG1, 23274 ± 386 for TG1: pBAD and 22435 ± 460 CPM 241 for TG1: pMnhF1). At various points after the initial incorporation of radiolabelled 242 cholic acid, cells were centrifuged and cell-associated radioactivity was determined 243 by liquid scintillation method. E. coli TG1 cells expressing MnhF retained 244 significantly (P<0.05) lower levels of 14 C-radiolabelled cholic acid than parental TG1 245 and TG1 cells with the empty pBAD vector (TG1: pBAD) (Fig 3B) . In both sets of 246 experiments the reason for increasing cell-associated radiolabel during the efflux 247 period, after which cells have been diluted in excess non-labelled cholic acid, is 248 unclear, but has also been observed in previous studies on Listeria monocytogenes 249 and may reflect continued incorporation of 14 C-cholic acid during the efflux period 250 after dilution (25). 251 252 Bile salt resistance is not affected by agr. 253
To examine whether agr quorum sensing system is involved in bile salt resistance, the 254
MICs for CA, DCA and CDCA in S. aureus SH1001 (agr) were determined and 255 found to be indistinguishable from those of the wild type (results not shown). 256
Furthermore, the agr system is not inhibited by the mnhF mutation as the RNAIII 257 effector molecule is still produced (Fig 4) . Thus we were unable to demonstrate a role 258 for agr in bile resistance. 10 cfu/mL, as a single dose, the S. aureus 278 populations stabilised at 6 to 7 Log 10 units over a period of up to 8 hours. Survival of 279 S. aureus ∆mnhF was significantly attenuated compared to its parental strain in all 280 three vesels (Fig 5A-C) . 
Salmonella enterica and Vibrio cholera regulate intestinal colonisation and virulence 322
in response to bile (50, 51). However pathogens that inhabit the human intestines are 323 also exposed to the bactericidal nature of bile salts and hence must also exhibit 324 resistance in order to survive. Generally, Gram-negative bacteria are more innately 325 resistant than Gram positives, due to the presence of an outer membrane, which acts 326 as a barrier (38). Indeed maintenance of membrane integrity by lipopolysaccharide 327 (LPS) in the cellular envelope of Gram-negative bacteria imparts protection against 328 the actions of bile salts (52, 53). Salmonella typhi and Salmonella typhimurium are 329 able to grow at bile concentrations that are much higher than those encountered in 330
vivo. This is due, at least in part, to the presence of outer membrane efflux pumps 331 such as AcrAB (54) . Similarly, HefC is an AcrB homologue that confers bile salt 332 
